5α-reductase inhibitors, such as finasteride and dutasteride, decrease the size of the prostate and the serum PSA level. Do these agents also impact on the PCA3 Score? 

Does the PCA3 Score only help in deciding whether a biopsy is needed or can it also aid in differentiating significant (aggressive) from insignificant (indolent) cancer?

Can the PCA3 Score be used to aid in the decision to perform a biopsy of a patient without a family history of prostate cancer, a normal digital rectal examination and a moderately elevated (low-moderately high) serum prostate specific antigen (PSA) level (e.g. 9.1 ng/mL at an age of 69 years)?

Can the PCA3 test be used to monitor disease response and/or recurrence of prostate cancer after local or systemic therapy?

Is the PCA3 Score age-dependent?

Can the  PCA3 Score aid in the decision to perform a biopsy in a relatively young patient, with no family history of prostate cancer, a normal digital rectal examination (DRE) and a serum prostate specific antigen level (PSA) at or slightly higher than normal for his age?

Does recent ejaculation affect the PCA3 score?

Can the PCA3 test aid in the decision whether a biopsy is needed in men suspected of having prostate cancer but who have been previously treated for prostatitis?

Can the PCA3 Score aid in the decision to perform a prostate biopsy in men who have known genetic variations linked to an increased prostate cancer risk (e.g. a BCRA2 mutation) either themselves or in their immediate family?